Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
University of Illinois at Chicago
Modality
Small molecule
Development Phase
Phase 1
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
37High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT01639911CT.gov Phase I Study of MLN8237 and Pazopanib in Patients With Solid Tumors | — | Completed | — | — | — |
NCT01375699CT.gov Doxorubicin With or Without Sildenafil, With Analysis of Cardiac Markers | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Malignant Urinary System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | University of Illinois at Chicago | P1 | CCC · 48 |
| Nivolumab | Spanish Oncology Genito-Urinary Group | P2 | B |
| Tadalafil | Regina Elena Cancer Institute | P3 | B |
| Ipilimumab | Dana-Farber Cancer Institute | P2 | B |
| Atezolizumab | British Columbia Cancer Agency | P2 | B |
| Riluzole | University of California, Irvine | P2 | CCC |
| Amcasertib | Sumitomo Pharma America, Inc. | P2 | CCC |
| Toripalimab | Shanghai Junshi Bioscience Co., Ltd. | P1 | CC |
| Pazopanib | University of Illinois at Chicago | P1 | CC |
+21 more in the Malignant Urinary System Neoplasm cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Malignant Urinary System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-malignant-urinary-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →